Nxera Pharma (formerly Sosei Heptares)

Nxera Pharma, formerly known as Sosei Heptares, is a pioneering biopharmaceutical company based in the UK, dedicated to transforming the treatment landscape for patients with serious diseases. The company focuses on the discovery and development of novel medicines that target G protein-coupled receptors (GPCRs), which play a crucial role in various physiological processes.

With a robust pipeline of innovative drug candidates, Nxera Pharma aims to address unmet medical needs in areas such as neurology, immunology, and oncology. The company’s proprietary StaR® technology platform enables the design of stabilised receptor variants, facilitating the discovery of high-quality drug candidates.

Core Activities:

• Research and development of GPCR-targeted therapies.
• Collaboration with leading pharmaceutical companies to enhance drug discovery efforts.
• Advancing clinical trials to bring new treatments to market.

Nxera Pharma is committed to scientific excellence and innovation, striving to improve patient outcomes through its cutting-edge research. The company’s vision is to become a leader in the biopharmaceutical industry by leveraging its unique technologies and expertise.

Headquartered in the UK, Nxera Pharma fosters a culture of collaboration and integrity, attracting top talent in the field. The company believes in the power of partnerships and actively seeks collaborations that align with its mission to develop life-changing therapies.

As Nxera Pharma continues to grow, it remains focused on its core values of patient-centricity, scientific rigor, and ethical responsibility, ensuring that every step taken is towards a healthier future for all.